Skip to content

Clinical Trial of Postmastectomy Radiotherapy in Breast Cancer With One to Three Positive Nodes

A Phase Ⅲ Randomized Clinical Trial of Postmastectomy Radiotherapy in Breast Cancer With One to Three Positive Nodes

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00805597
Enrollment
40
Registered
2008-12-09
Start date
2008-06-30
Completion date
2012-02-29
Last updated
2016-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

breast cancer, mastectomy, one to three positive nodes, radiotherapy

Brief summary

The purpose of this study is to evaluate postmastectomy radiotherapy in breast cancer patients with one to three positive nodes.

Detailed description

Eligible breast cancer patients with mastectomy and axillary dissection are randomized into 2 groups:radiotherapy of 50 Gy in 25 fractions within 5 weeks to ipsilateral chest wall and supraclavicular nodal region,and no radiotherapy. During and after radiotherapy, the patients are followed and the efficacy and toxicities of radiotherapy are evaluated.

Interventions

RADIATIONradiation

radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region

RADIATIONno radiation

no radiotherapy

Sponsors

Chinese Academy of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Ipsilateral histologically confirmed invasive breast cancer * Undergone total mastectomy and axillary dissection * T1-2 and one to three axillary lymph nodes positive * A minimum of 10 axillary nodes dissected * Fit for chemotherapy(if indicated),endocrine therapy(if indicated)and postoperative irradiation * Written,informed consent

Exclusion criteria

* Patients who undergone previous irradiation to the ipsilateral chest wall and supraclavicular region * Previous or concurrent malignant other than non-melanomatous skin cancer * Unable or unwilling to give informed consent

Design outcomes

Primary

MeasureTime frame
overall survival10 years

Secondary

MeasureTime frame
loco-regional recurrence5 years

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026